FILTER

FILTERED INTERVIEW RESULTS

Arda Ural

PARTNER & AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES AND WELLNESS, EY
"The biotech sector has room to grow. Oncology, blood disorders, immunology, inflammation, rare diseases, and neurology are key therapeutic areas attracting capital and fostering innovation."

Gil Roth

PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"There are signs of funding returning in the first half of this year, potentially revitalizing early-stage projects, and benefiting the CDMO sector."

Hernan Bazan

CEO AND CO-FOUNDER, SOUTH RAMPART PHARMA
“The best way to attract investment is with serious science and well-validated clinical mechanisms of action. An asset in the clinic with a well-described mechanism of action for how it works and peer-reviewed science, including NIH funding, helps with the validity.”

Steve Tallant

SENIOR DIRECTOR, SOLUTION MARKETING GROUP AT SYSTECH, A SOLUTIONS DIVISION OF MARKEM-IMAJE
"We are taking a physical supply chain and creating a digital twin of products and data moving through the chain."

Tim Tyson

CHAIRMAN AND CEO, TRIRX PHARMACEUTICAL SERVICES
"Our focus on capacity utilization, market demand, and strategic acquisitions will be key drivers of TriRx's growth in the coming year."

Trevor Caswell

CHAIRMAN, PHARMA.AERO
"Pharma.Aero is a unique collaborative platform connecting life sciences shippers and service providers to achieve reliable end-to-end air transport for pharmaceutical cargo."

Denise Juliano

GROUP VICE PRESIDENT, LIFE SCIENCES, PREMIER INC.
"Our technology and data capabilities help researchers and providers gain insights into health inequities and support strategies and solutions to advance health equity."

Cory Lewis

CEO, PRESIDENT AND CO-FOUNDER, INCOG BIOPHARMA SERVICES
"Wrapping up Q1 in 2023 we are now above 80 employees with a facility that is cGMP production ready and actively manufacturing commercial PPQ batches for one of our biopharma clients."

Katrin Rupalla

CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."

Stefan Randl & Paul Spencer

HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT (PS), EVONIK HEALTH CARE
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Western USA Mining 2024

GBR's Western USA Mining 2024 report offers a comprehensive overview of the current state of the mining industry and what Washington and all stakeholders across the mining value chain are doing to achieve mineral independence.

PARTNER EVENTS